DE69003595T2 - Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel. - Google Patents

Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel.

Info

Publication number
DE69003595T2
DE69003595T2 DE90401432T DE69003595T DE69003595T2 DE 69003595 T2 DE69003595 T2 DE 69003595T2 DE 90401432 T DE90401432 T DE 90401432T DE 69003595 T DE69003595 T DE 69003595T DE 69003595 T2 DE69003595 T2 DE 69003595T2
Authority
DE
Germany
Prior art keywords
microproteins
residue
norleucine
preparation
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE90401432T
Other languages
English (en)
Other versions
DE69003595D1 (de
Inventor
Bertrand Castro
Anne Favel
Dung Le-Nguyen Dung Le-Nguyen
Maria-Antonia Previero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of DE69003595D1 publication Critical patent/DE69003595D1/de
Publication of DE69003595T2 publication Critical patent/DE69003595T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE90401432T 1989-05-31 1990-05-30 Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel. Expired - Fee Related DE69003595T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8907155A FR2647677B1 (fr) 1989-05-31 1989-05-31 Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines

Publications (2)

Publication Number Publication Date
DE69003595D1 DE69003595D1 (de) 1993-11-04
DE69003595T2 true DE69003595T2 (de) 1994-02-17

Family

ID=9382205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE90401432T Expired - Fee Related DE69003595T2 (de) 1989-05-31 1990-05-30 Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel.

Country Status (8)

Country Link
US (1) US5089474A (de)
EP (1) EP0401109B1 (de)
JP (1) JPH0368599A (de)
AT (1) ATE95195T1 (de)
CA (1) CA2017803A1 (de)
DE (1) DE69003595T2 (de)
ES (1) ES2060100T3 (de)
FR (1) FR2647677B1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432155A (en) * 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
RU2151611C1 (ru) * 1999-06-18 2000-06-27 Общество с ограниченной ответственностью НАУЧНО-ПРОИЗВОДСТВЕННОЕ ПРЕДПРИЯТИЕ "МЕДБИОФАРМ" Средство для регулирования йодного обмена или профилактики йоддефицитных состояний
US7297350B2 (en) * 2002-08-09 2007-11-20 Kentara Research Llc Evaporate of Ecbalium elaterium fruit extract for treating viral symptoms
US7282227B2 (en) * 2002-08-09 2007-10-16 Kentara Research Llc Method for treating hepatitis C with evaporate of Ecballium elaterium extract
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) * 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3230275A1 (de) * 1982-08-14 1984-02-16 Bayer Ag, 5090 Leverkusen Elastaseinhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
WO1986003497A1 (en) * 1984-12-06 1986-06-19 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors

Also Published As

Publication number Publication date
EP0401109B1 (de) 1993-09-29
FR2647677B1 (fr) 1991-09-27
FR2647677A1 (fr) 1990-12-07
CA2017803A1 (fr) 1990-11-30
ATE95195T1 (de) 1993-10-15
EP0401109A1 (de) 1990-12-05
DE69003595D1 (de) 1993-11-04
US5089474A (en) 1992-02-18
JPH0368599A (ja) 1991-03-25
ES2060100T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
DE69003595T2 (de) Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel.
ATE363535T1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
HU906177D0 (en) Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
CA2117466A1 (fr) Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des maladies du motoneurone
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
DE69033040T2 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
FR2695317B1 (fr) Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
ATE84048T1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
CA2061569A1 (en) Improved activation of recombinant proteins
KR910002899A (ko) 혈조절 펩타이드
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
ATE138936T1 (de) Neue peptidderivate, verfahren zu deren herstellung und deren anwendung als heilmittel
ITMI910658A0 (it) N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
HUP9602024A2 (hu) Aminosavtartalmú, külsőlegesen használható, gyógyhatású készítmény
EP0294667A3 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives
ATE141615T1 (de) Neue peptid-derivate mit bradikyninantagonischer wirkung, verfahren zur deren herstellung und pharmazeutische zubereitungen die sie enthalten
EP0373613A3 (de) Pyridin-3-percarboxylsäure monopersulfat
DE69007010T2 (de) Nichtfestes Augenarzneimittel und Verfahren zur Herstellung dieses Arzneimittels.
EP0722714A3 (de) Benzoxazolderivate, ihre Verwendung als Sonnenschutzmittel und die Benzoxazolderivate enthaltende kosmetische Zusammensetzungen
EP0351676A3 (de) Benzothiazolone
ES2135389T3 (es) Antagonistas de endotelina.
ATE149T1 (de) 2-(n-(2'-chlor-4'-methylthienyl-3')-n-(cyclopropyl- methyl)-amino)-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung.
ES2140329A1 (es) Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee